Mirati Therapeutics, Inc.
MRTX
Kedudukan dalam Saham
#4928
Mirati Therapeutics, Inc. is a U.S.-based biotechnology firm operating at the... Mirati Therapeutics, Inc. is a U.S.-based biotechnology firm operating at the clinical stage, committed to identifying and developing treatments that target the genetic and immunological factors driving cancer progression. Its pipeline features MRTX849, a KRAS G12C inhibitor currently undergoing Phase 1/2 clinical trials for a range of malignancies, including non-small cell lung, colorectal, and pancreatic cancers. Additionally, the company is advancing Sitravatinib, an investigational broad-spectrum kinase inhibitor, which has reached Phase 3 clinical trials specifically for non-small cell lung cancer. Mirati also has a KRAS G12D inhibitor program in its preclinical development phase. The company has forged a collaboration and licensing agreement with BeiGene, Ltd. for the development, manufacturing, and commercialization of sitravatinib. Established in 1995, Mirati Therapeutics, Inc. maintains its headquarters in San Diego, California.
Harga Saham
$58.70
Disegerakkan terakhir: 2024-01-23
Modal Pasaran
$2.98B
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
0.00%
Negara
US
Perdagangan Mirati Therapeutics, Inc. (MRTX)
Kategori
Healthcare
Sejarah hasil dividen untuk Mirati Therapeutics, Inc. (MRTX)
Hasil dividen (TTM) bagi Mirati Therapeutics, Inc. (simbol saham: MRTX) pada 2026 adalah: 0
Purata hasil dividen 5 tahun terakhir: 0.00%
Purata hasil dividen 5 tahun terakhir: 0.00%
Sejarah hasil dividen untuk Mirati Therapeutics, Inc. (MRTX) dari 2026 hingga 2026
Hasil dividen pada akhir setiap tahun (TTM)
| Tahun | Hasil Dividen | Ubah |
|---|---|---|
| Tidak cukup data untuk tarikh yang disediakan. | ||
Hasil dividen (TTM) untuk syarikat serupa atau pesaing
| Syarikat | Hasil Dividen | Negara |
|---|---|---|
| 0.00% |
US
|
|
| 0.00% |
US
|
|
| 2.17% |
AU
|
|
| 0.00% |
NL
|
|
| 0.00% |
CH
|
